Clinical Trials
25 trialsReduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
CONTRAC
Dana-Farber Cancer Institute
STOP2
Children's Hospital Medical Center, Cincinnati
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
MaineHealth
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
SOS
University of Pennsylvania
Sirolimus in Treating Patients With Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Sarcoma Alliance for Research through Collaboration
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Maastricht Radiation Oncology
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
University of Washington
EMN-alloRIC
European Myeloma Network B.V.
Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma
Grupo Espanol de Investigacion en Sarcomas
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center